课题基金 / 基金详情

Small molecule agonists of the relaxin receptor

Small molecule agonists of the relaxin receptor
松弛素受体的小分子激动剂
批准号:
7758639
负责人:
Alexander I Agoulnik
金额:
$2.5万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2011-08-31

项目摘要

项目成果

Alexander I Agoulnik的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The relaxin hormone is involved in the variety of biological functions in health and disease conditions. The role of relaxin is well-established in female reproduction and parturition, mammary gland and endometrial development, maintenance of myometrial quiescence during pregnancy. Relaxin signaling through its G protein-coupled receptor RXFP1 results in extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation and overall tissue homeostasis. Significantly, the therapeutic effects of relaxin in the treatment of renal, cardiac, skin, lung fibrosis, inflammation, and wound healing in animal models are well-established. Other data strongly indicate on the significance of relaxin in progression of prostate, breast, thyroid, endometrial and other cancers. Several clinical trials study the therapeutic role of relaxin in treatment of scleroderma, cervical ripening, fibromyalgia, orthodontics and as a protective agent in congestive heart failure. The easy and reliable indication of relaxin receptor activation in cells expressing RXFP1 is an increase of cAMP production. No chemical/small molecules or non-peptide agonists/antagonists are known for relaxin receptor. The current application is designed to fill this gap through high throughput small molecule agonist screening. Using HEK293T cells stably transfected with relaxin receptor we have optimized commercially available cAMP assay for a 1536-well plate format and performed trial screens of validation library. The assay is suitable for high throughput screening. After primary screen the active compounds will be selected in a series of secondary screens to identify specific relaxin receptor agonists. The discovery of relaxin agonists will provide basis for their use as anti-fibrotic, proliferative, vasodilatory, and angiogenic agents. PUBLIC HEALTH RELEVANCE: Relaxin is a peptide hormone with anti-fibrotic, angiogenic, vasodilatory, and cell-growth stimulating properties. The main goal of the application is to identify small molecule agonists of relaxin receptor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small molecule agonists of insulin-like3 receptor for treatment of osteoporosis
  • 批准号:
    9144926
  • 项目类别:
  • 资助金额:
    $25.52万
  • 财政年份:
    2016
  • 负责人:
    Alexander I Agoulnik
  • 依托单位:
Small molecule agonists of insulin-like3 receptor for treatment of osteoporosis
  • 批准号:
    9313172
  • 项目类别:
  • 资助金额:
    $31.52万
  • 财政年份:
    2016
  • 负责人:
    Alexander I Agoulnik
  • 依托单位:
Small molecule antagonists of relaxin receptor
  • 批准号:
    8558698
  • 项目类别:
  • 资助金额:
    $29.74万
  • 财政年份:
    2013
  • 负责人:
    Alexander I Agoulnik
  • 依托单位:
Small molecule antagonists of relaxin receptor
  • 批准号:
    8735900
  • 项目类别:
  • 资助金额:
    $28.83万
  • 财政年份:
    2013
  • 负责人:
    Alexander I Agoulnik
  • 依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: